Peripheral O
and O
prefrontal O
stress O
system O
markers O
and O
risk O
of O
relapse O
in O
alcoholism O
Previous O
research O
has O
shown O
that O
hyperactivation O
in O
ventral O
medial O
prefrontal O
cortex O
( O
VmPFC O
) O
and O
rostral O
anterior O
cingulate O
cortex O
( O
rACC O
) O
and O
high O
cortisol O
to O
corticotrophin O
ratio O
( O
cort O
: O
ACTH O
ratio O
) O
during O
neutral-relaxed O
states O
predict O
relapse O
in O
alcohol O
dependent O
( O
AD O
) O
patients O
. O

Other O
studies O
have O
shown O
that O
VmPFC/rACC O
deactivation O
and O
blunted O
cortisol O
release O
to O
stress O
and O
alcohol O
cues O
are O
predictive O
of O
time O
to O
relapse O
and O
relapse O
severity O
. O

However O
, O
no O
previous O
study O
has O
assessed O
the O
relationship O
between O
these O
markers O
of O
central O
and O
peripheral O
nervous O
system O
dysfunction O
in O
AD O
participants O
and O
their O
potential O
joint O
effects O
on O
relapse O
risk O
. O

Forty O
early O
abstinent O
, O
treatment O
engaged O
AD O
patients O
underwent O
a O
laboratory O
experiment O
with O
exposure O
to O
neutral O
, O
alcohol O
, O
and O
stress O
cues O
and O
a O
separate O
functional O
magnetic O
resonance O
imaging O
( O
fMRI O
) O
scan O
with O
similar O
cue O
exposure O
. O

Neutral-relaxed O
state O
cort O
: O
ACTH O
ratio O
was O
significantly O
associated O
with O
VmPFC O
hyperreactivity O
to O
neutral-relaxing O
cues O
, O
and O
also O
with O
hypoactivation O
in O
response O
to O
alcohol O
and O
stress O
cues O
in O
AD O
patients O
. O

Basal O
heart O
rate O
, O
neutral O
cort O
: O
ACTH O
ratio O
, O
and O
neutral O
VmPFC O
hyperreactivty O
were O
each O
associated O
with O
risk O
of O
relapse O
. O

However O
, O
abnormal O
VmPFC O
activation O
and O
elevated O
cort O
: O
ACTH O
ratio O
overlap O
in O
predicting O
risk O
for O
relapse O
, O
and O
dysfunctional O
VmPFC O
response O
was O
the O
sole O
significant O
predictor O
of O
odds O
of O
relapse O
in O
a O
joint O
model O
of O
relapse O
risk O
. O

These O
findings O
suggest O
that O
the O
Cort O
: O
ACTH O
ratio O
may O
serve O
as O
a O
peripheral O
marker O
of O
VmPFC O
brain O
dysfunction O
while O
aberrant O
VmPFC O
responses O
needs O
further O
evaluation O
as O
a O
potential O
biomarker O
of O
alcohol O
relapse O
risk O
in O
clinical O
outcome O
studies O
. O

Methods O
Participants O
For O
the O
current O
report O
, O
we O
included O
forty O
recovering O
AD O
patients O
( O
9 O
female O
; O
aged O
18–50 O
years O
) O
who O
had O
abstained O
from O
alcohol O
for O
4 O
to O
8 O
weeks O
( O
mean O
[ O
SD O
] O
: O
34 O
( O
7.6 O
) O
days O
; O
range O
, O
29–59 O
days O
) O
. O

All O
patients O
were O
residing O
in O
an O
inpatient O
treatment O
research O
facility O
and O
were O
actively O
engaged O
in O
substance O
abuse O
treatment O
for O
at O
least O
4 O
weeks O
. O

Individuals O
currently O
using O
opiates O
, O
those O
who O
ever O
met O
criteria O
for O
opiate O
dependence O
, O
and O
those O
taking O
prescribed O
, O
over O
the O
counter O
, O
or O
homeopathic O
medications O
for O
any O
current O
psychiatric O
or O
medical O
condition O
were O
excluded O
. O

Women O
were O
excluded O
from O
the O
study O
if O
they O
were O
using O
hormonal O
contraceptives O
or O
were O
in O
the O
follicular O
or O
early O
and O
mid-luteal O
phases O
during O
laboratory O
and O
fMRI O
sessions O
. O

All O
subjects O
underwent O
a O
complete O
medical O
evaluation O
, O
including O
electrocardiography O
and O
laboratory O
tests O
of O
renal O
, O
hepatic O
, O
pancreatic O
, O
hematopoietic O
, O
and O
thyroid O
functions O
, O
to O
ensure O
good O
physical O
health O
. O

All O
study O
procedures O
were O
approved O
by O
the O
Human O
Investigation O
Committee O
of O
the O
Yale O
University O
School O
of O
Medicine O
and O
all O
participants O
signed O
a O
written O
informed O
consent O
. O

The O
laboratory O
and O
fMRI O
studies O
were O
conducted O
1 O
month O
after O
admission O
to O
the O
inpatient O
unit O
to O
allow O
for O
normalization O
of O
neurobiological O
changes O
associated O
with O
acute O
alcohol O
withdrawal O
and O
to O
assess O
stress O
responses O
and O
craving O
in O
the O
early O
recovery O
period O
. O

Abstinence O
from O
drug O
and O
alcohol O
consumption O
during O
treatment O
was O
verified O
by O
urinalysis O
. O

Four O
structured O
smoking O
breaks O
were O
allowed O
in O
the O
inpatient O
treatment O
facility O
and O
subjects O
were O
permitted O
to O
smoke O
1–2 O
cigarettes O
during O
each O
break O
. O

The O
smoke O
breaks O
were O
implemented O
at O
the O
start O
of O
inpatient O
admission O
at O
least O
4 O
weeks O
prior O
to O
laboratory O
and O
fMRI O
testing O
, O
and O
thus O
AD O
patients O
had O
a O
4 O
week O
period O
to O
adapt O
to O
this O
schedule O
of O
nicotine O
consumption O
. O

This O
sample O
made O
up O
about O
half O
( O
43 O
% O
) O
of O
the O
sample O
reported O
on O
in O
the O
study O
and O
the O
majority O
( O
89 O
% O
) O
of O
the O
sample O
reported O
on O
in O
the O
study O
( O
see O
Figure O
S1 O
for O
a O
flowchart O
of O
the O
current O
study O
sample O
utilized O
from O
those O
reported O
in O
previous O
reports O
) O
. O

The O
criteria O
for O
inclusion O
in O
the O
present O
study O
was O
any O
AD O
patient O
who O
met O
the O
above O
described O
inclusion O
and O
exclusion O
criteria O
and O
also O
completed O
both O
the O
fMRI O
and O
the O
laboratory O
experiment O
during O
the O
4–8 O
week O
period O
of O
their O
inpatient O
stay O
, O
and O
also O
completed O
the O
90-day O
prospective O
followup O
period O
for O
assessment O
of O
relapse O
risk O
. O

Individualized O
imagery O
method O
and O
script O
development O
Lab O
All O
participants O
underwent O
an O
imagery O
script O
development O
session O
( O
week O
3 O
of O
admission O
) O
during O
which O
they O
were O
asked O
to O
identify O
a O
highly O
stressful O
event O
from O
their O
own O
lives O
( O
rated O
by O
the O
subject O
as O
greater O
than O
8 O
on O
a O
10-point O
Likert O
scale O
for O
stressfulness O
) O
; O
a O
personal O
alcohol O
cue– O
related O
event O
that O
involved O
people O
, O
places O
, O
and O
objects O
related O
to O
alcohol O
use O
and O
led O
to O
subsequent O
alcohol O
use O
; O
and O
a O
personal O
neutral O
, O
relaxing O
event O
. O

Details O
of O
each O
situation O
were O
elicited O
using O
methods O
reviewed O
and O
summarized O
in O
. O

Scripts O
were O
developed O
using O
a O
standardized O
format O
, O
based O
on O
specific O
stimulus O
and O
response O
details O
of O
each O
situation O
, O
and O
then O
audiotaped O
for O
presentation O
in O
the O
laboratory O
sessions O
. O

MRI O
Two O
additional O
personalized O
scripts O
for O
each O
of O
the O
stress O
, O
alcohol O
cue O
and O
neutral-relaxing O
conditions O
were O
developed O
prior O
to O
the O
fMRI O
session O
according O
to O
the O
procedure O
described O
above O
. O

Each O
2-minute O
script O
was O
audiotaped O
and O
presented O
in O
random O
order O
during O
the O
scanning O
session O
. O

The O
neutral-relaxing O
script O
served O
as O
an O
active O
control O
state O
for O
the O
stress O
and O
alcohol O
cues O
because O
it O
has O
been O
shown O
not O
to O
increase O
alcohol O
craving O
and O
it O
controls O
for O
the O
nonspecific O
effects O
of O
the O
experimental O
manipulation O
. O

Laboratory O
Sessions O
On O
a O
day O
prior O
to O
the O
laboratory O
sessions O
, O
participants O
took O
part O
in O
a O
habituation O
and O
imagery O
training O
procedure O
that O
involved O
exposure O
to O
the O
stress O
of O
intravenous O
catheter O
insertion O
and O
specific O
instructions O
on O
progressive O
relaxation O
and O
guided O
imagery O
participation O
. O

This O
was O
followed O
by O
3 O
experimental O
sessions O
conducted O
at O
7:45 O
AM O
on O
each O
of O
3 O
consecutive O
days O
where O
subjects O
were O
exposed O
to O
5-minute O
audiotaped O
scripts O
of O
stress O
, O
alcohol-related O
, O
and O
neutral O
, O
relaxing O
scenarios O
. O

Only O
1 O
stimulus O
script O
was O
presented O
per O
session O
and O
condition O
order O
was O
randomized O
and O
counterbalanced O
across O
participants O
. O

HPA O
Axis O
Measures O
To O
assess O
basal O
plasma O
levels O
of O
ACTH O
and O
cortisol O
, O
4 O
mL O
of O
blood O
were O
collected O
in O
a O
heparinized O
tube O
that O
was O
placed O
on O
ice O
immediately O
after O
the O
blood O
was O
drawn O
. O

Within O
30 O
minutes O
of O
collection O
, O
the O
blood O
was O
centrifuged O
at O
4°C O
and O
the O
plasma O
was O
pooled O
and O
aliquoted O
for O
ACTH O
and O
cortisol O
assays O
. O

All O
tubes O
were O
stored O
at O
−70°C O
and O
analyzed O
using O
standard O
radioimmunoassay O
procedures O
as O
reported O
previously O
. O

Because O
cortisol O
secretion O
from O
the O
adrenal O
glands O
occurs O
in O
response O
to O
circulating O
ACTH O
, O
the O
cort O
: O
ACTH O
ratio O
serves O
as O
a O
measure O
of O
adrenal O
sensitivity O
. O

Functional O
Magnetic O
Resonance O
Imaging O
Acquisition O
and O
Procedure O
Magnetic O
resonance O
imaging O
data O
were O
collected O
using O
a O
3-T O
Siemens O
Trio O
MRI O
system O
equipped O
with O
a O
standard O
quadrature O
head O
coil O
, O
using O
T2 O
* O
-sensitive O
gradient-recalled O
single O
shot O
echo O
planar O
pulse O
sequence O
( O
parameters O
described O
in O
) O
. O

Six O
fMRI O
trials O
( O
2 O
per O
condition O
) O
were O
acquired O
using O
a O
block O
design O
. O

The O
order O
of O
the O
6 O
trials O
were O
randomized O
and O
counterbalanced O
across O
participants O
. O

Each O
script O
was O
presented O
only O
once O
for O
a O
participant O
, O
and O
scripts O
in O
the O
same O
condition O
were O
not O
presented O
consecutively O
. O

Each O
trial O
lasted O
5 O
minutes O
, O
including O
a O
1.5-minute O
quiet O
baseline O
period O
followed O
by O
2.5-minute O
imagery O
period O
( O
2 O
minutes O
of O
read O
imagery O
and O
0.5 O
minutes O
of O
quiet O
imagery O
) O
and O
a O
1-minute O
quiet O
recovery O
. O

During O
baseline O
, O
participants O
were O
instructed O
to O
stay O
still O
in O
the O
scanner O
without O
engaging O
in O
any O
mental O
activity O
. O

Between O
each O
trial O
, O
participants O
were O
engaged O
in O
2-minute O
progressive O
relaxation O
to O
normalize O
any O
residual O
anxiety O
or O
craving O
from O
the O
prior O
trial O
. O

This O
technique O
was O
mainly O
focused O
on O
relaxing O
physiological O
muscle O
tension O
in O
specific O
muscle O
groups O
and O
did O
not O
involve O
mental O
relaxation O
or O
imagery O
. O

fMRI O
Statistical O
Analysis O
Individual O
Subject O
Level O
Functional O
MRI O
data O
were O
converted O
from O
Digital O
Imaging O
and O
Communication O
in O
Medicine O
format O
to O
analyze O
( O
nifti O
) O
format O
using O
XMedCon O
. O

To O
achieve O
steady-state O
equilibrium O
between O
radiofrequency O
pulsing O
and O
relaxation O
, O
the O
first O
10 O
images O
of O
each O
trial O
were O
discarded O
. O

Images O
were O
slice-time O
corrected O
using O
a O
custom-designed O
MATLAB O
program O
. O

Motion O
correction O
was O
implemented O
using O
Statistical O
Parametric O
Mapping O
version O
5 O
for O
3 O
translational O
and O
3 O
rotational O
directions O
, O
removing O
trials O
with O
linear O
motion O
greater O
than O
1.5mm O
and O
a O
rotation O
exceeding O
2 O
mm O
. O

The O
recovery O
period O
( O
1 O
minute O
) O
was O
excluded O
from O
the O
data O
analysis O
to O
prevent O
carryover O
effects O
from O
the O
imagery O
period O
. O

Individual-level O
analysis O
was O
conducted O
using O
a O
general O
linear O
model O
on O
each O
voxel O
in O
the O
entire O
brain O
volume O
with O
a O
task O
specific O
regressor O
( O
2.5-minute O
imagery O
relative O
to O
a O
1.5-minute O
baseline O
) O
using O
Yale O
BioImageSuite30 O
( O
http O
: O
//www.bioimagesuite.org/ O
) O
. O

To O
account O
for O
potential O
variability O
in O
baseline O
fMRI O
signal O
, O
drift O
correction O
was O
included O
in O
the O
general O
linear O
model O
. O

Each O
trial O
was O
normalized O
against O
the O
immediate O
baseline O
period O
preceding O
the O
script O
and O
then O
the O
2 O
trials O
of O
the O
same O
type O
were O
averaged O
. O

Functional O
images O
were O
spatially O
smoothed O
with O
a O
6-mm O
Gaussian O
kernel O
, O
resulting O
in O
normalized O
beta O
maps O
in O
the O
acquired O
space O
( O
3.44 O
mm_3.44 O
mm_4 O
mm O
) O
. O

To O
adjust O
for O
individual O
anatomical O
differences O
, O
3 O
registrations O
were O
performed O
using O
the O
Yale O
BioImageSuite O
program O
: O
a O
linear O
individual O
registration O
of O
raw O
functional O
image O
into O
a O
2-dimensional O
anatomical O
image O
, O
2-dimensional O
to O
3-dimensional O
( O
1 O
mm_1mm_1 O
mm O
) O
linear O
registration O
, O
and O
a O
nonlinear O
registration O
to O
the O
reference O
3-dimensional O
Montreal O
Neurological O
Institute O
image O
. O

Group O
Level O
: O
Whole O
Brain O
Correlations O
Whole O
brain O
voxel-wise O
correlation O
analyses O
were O
run O
to O
determine O
the O
relationship O
between O
blood O
oxygen O
level O
dependent O
( O
BOLD O
) O
response O
to O
stress O
, O
neutral O
, O
and O
alcohol O
cues O
and O
laboratory O
session O
hormonal O
measurements O
at O
baseline O
and O
in O
response O
to O
neutral O
, O
alcohol O
, O
and O
stress O
cues O
. O

A O
family-wise O
error O
correction O
was O
applied O
to O
correct O
for O
multiple O
comparisons O
based O
on O
a O
MonteCarlo O
Simulation O
run O
in O
AFNI O
AlphaSim O
( O
p O
< O
0.05 O
, O
cluster O
size O
minimum=168 O
voxels O
) O
. O

To O
account O
for O
extreme O
values O
, O
90 O
% O
winsorization O
was O
applied O
to O
the O
cort O
: O
ACTH O
ratio O
of O
two O
outliers O
, O
whose O
heart O
rate O
and O
ROI O
Beta O
values O
were O
beyond O
2 O
standard O
deviations O
from O
the O
mean O
. O

Ninety O
percent O
winsorization O
is O
the O
process O
of O
determining O
the O
value O
of O
the O
95th O
and O
5th O
percentiles O
of O
a O
given O
measure O
and O
setting O
any O
outliers O
to O
these O
values O
. O

Prospective O
Follow O
up O
All O
patients O
were O
followed O
up O
with O
face-to-face O
interviews O
conducted O
on O
days O
14 O
, O
30 O
, O
and O
90 O
post O
discharge O
to O
evaluate O
relapse O
outcomes O
using O
both O
urinalysis O
and O
breathalyzer O
samples O
, O
in O
addition O
to O
the O
Form O
90 O
substance O
use O
timeline O
follow-back O
calendar O
based O
interview O
, O
as O
reported O
in O
our O
previous O
studies O
. O

Relapse O
Prediction O
Analyses O
Beta O
values O
for O
the O
VmPFC O
ROI O
reported O
to O
be O
predictive O
of O
future O
relapse O
risk O
and O
heart O
rates O
responses O
during O
fMRI O
from O
for O
the O
subgroup O
of O
AD O
patients O
included O
in O
the O
current O
study O
were O
extracted O
for O
each O
of O
the O
neutral O
imagery-baseline O
, O
stress O
imagery- O
neutral O
imagery O
, O
and O
alcohol O
imagery-neutral O
imagery O
contrasts O
. O

Similarly O
, O
for O
the O
same O
subgroup O
of O
AD O
individuals O
, O
their O
neuroendocrine O
responses O
to O
stress O
and O
alcohol O
craving O
were O
extracted O
from O
the O
laboratory O
experiment O
that O
assessed O
peripheral O
stress O
responses O
and O
alcohol O
craving O
and O
relationship O
to O
relapse O
. O

Then O
independent O
analyses O
to O
test O
the O
proposed O
current O
analyses O
were O
conducted O
using O
Cox O
proportional O
hazard O
regressions O
, O
with O
time O
to O
alcohol O
relapse O
as O
a O
censoring O
variable O
, O
to O
investigate O
whether O
the O
VmPFC O
Beta O
values O
, O
cort O
: O
ACTH O
ratio O
, O
and O
heart O
rate O
predicted O
the O
time O
to O
first O
alcohol O
relapse O
and O
time O
to O
heavy O
drinking O
. O

